Table 2.
Rheumatoid Arthritis and Inflammatory Bowel Disease Cohort Descriptives
| RA (n=218) n, (%) |
IBD (n=190) n, (%) |
p value | |
|---|---|---|---|
| Age (mean +/− SD) | 60.5 +/− 13.9 | 49.8 +/− 16.0 | < 0.0001 |
| 20–34 | 9(4) | 43 (23) | |
| 35–49 | 35(16) | 52(27) | |
| 50–64 | 86(39) | 55(29) | |
| >65 | 88(40) | 40(21) | |
| Female | 181 (83) | 103 (54) | < 0.0001 |
| Caucasian | 197 (90) | 179 (94) | 0.15 |
| Crohn’s Disease | N/A | 115 (61) | |
| Ulcerative Colitis | 75 (39) | ||
| Tobacco Current User | 16 (7) | 13 (6) | 0.85 |
| PCP Specialty | |||
| Internal Medicine | 154 (70) | 122 (64) | |
| Family Medicine | 64 (29) | 67 (35) | |
| Medicaid | 14 (6) | 10 (5) | |
| Uninsured | 2 (1) | 4 (2) | |
| Charlson comorbidity index (mean, SD) | 1.7+/− 1.1 | 0.6 +/− (1.1) | < 0.0001 |
| Avg. PCP visits/year (mean, SD) | 1.9 +/−1.8 | 1.5 +/− 1.3 | 0.0085 |
| Avg. specialist visits/year (mean, SD) | 2.7 +/− 1.6 | 2.1 +/− 1.4 | < 0.0001 |
| Medications | |||
| Any immunosuppressant | 214 (98) | 142 (75) | < 0.0001 |
| Any Anti-TNF Therapy | 96 (44) | 77 (41) | 0.85 |
| TNF + Immunomodulator | 42 (19) | 30 (16) | 0.37 |
| Non-TNF biologic | 8(44) | 0 | n/a |
| Immunomodulator | 126 (58) | 81 (43) | 0.003 |
| Azathioprine/6MP | 4 (22) | 76 (40) | < 0.0001 |
| Methotrexate | 122 (56) | 5 (3) | < 0.0001 |
| Other DMARD* | 103 (47) | n/a | n/a |
| Mesalamine1 | 16 (7) | 97 (51) | < 0.0001 |
| Chronic Prednisone (>10mg for >60 days) | 76 (35) | 63(33) | 0.72 |
*
Other DMARD - hydroxycholorquine, leflunomide
1
Mesalamine - included sulfasalazine